Why drug developers are turning to this technique for rapid detection of replication-competent viruses.

Experts from the Access to Medicine Foundation discuss how to reduce the risk of antimicrobial resistance (AMR) in antibiotic manufacturing.

Clinical trials have improved greatly over the years, but there is still much to be done.

How do we encourage the development of new cell and gene therapies without compromising our ethics?

Countries that struggled to acquire COVID-19 vaccines have not forgotten the inequity, and are reminding pharma giants that they shouldn’t either

The Medicine Maker’s all-inclusive advent calendar…

Experts in the cell and gene therapy space are excited about things to come. After all, these are the pioneers of a burgeoning field of medicine.

A deep dive into the dangers of fentanyl entering the US supply chain – and the importance of the Drug Supply Chain Security Act

How the European Commission has struck deals to secure manufacturing capacity for future emergencies.

Exploring the ins and outs of a recent UK-based collaboration between two prominent advanced medicine players